Plain-English translation of NCT07615426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can help people with schizophrenia when added to their current antipsychotic medication. The study will check whether the medication is safe, whether patients can tolerate it well, and whether it's feasible to enroll and follow participants through the full study. About 64 people will participate, with half receiving the new medication and half receiving a placebo (inactive pill), and neither the patients nor the researchers will know who gets which until the study ends.
Current antipsychotic medications help many people with schizophrenia, but some patients continue to struggle with remaining symptoms. Researchers are exploring whether this medication could work as an add-on treatment to improve outcomes for people whose symptoms aren't fully controlled by their current medication alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication or a placebo alongside your regular antipsychotic medication. You will visit the research clinic for assessments that measure your symptoms, safety, and how well you tolerate the treatment. The study uses a double-blind design, meaning neither you nor the research team will know whether you're receiving the active medication or placebo, which helps ensure fair and unbiased results.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States